aguiar joins aisling capital  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital aguiar joins aisling capital january   by luisa beltran follow luisarbeltran eric aguiar md has joined aisling capital as a partner dr aguiar was previously a partner at thomas mcnerney  partners and before that he was a managing director of healthcare ventures press release new york jan   prnewswire — aisling capital a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products services and technologies announced that eric aguiar md has joined the firm as a partner dr aguiar who brings to aisling experience in drug development commercialization and strategic leadership will invest in biopharma opportunities across a range of therapeutic areas and stages of development “we are delighted to welcome eric to the team” said steve elms managing partner at aisling capital “many of us have had the pleasure of working with eric over the years witnessing firsthand the business acumen and drug development and commercial expertise that he brings to each endeavor—and we’re thrilled he’ll now be applying those strengths as a member of aisling’s investing practice his proven track record as an operator and entrepreneur coupled with his extensive network across the healthcare industry will also make him a highly valued resource to our portfolio” “eric has over  years of experience in the healthcare industry in a variety of clinical business strategy product and technology leadership roles we are delighted to welcome him to aisling capital” said drew schiff managing partner at aisling capital prior to joining aisling dr aguiar was a partner at thomas mcnerney  partners and before that he was a managing director of healthcare ventures both healthcare focused venture capital firms “i am very excited to join aisling capital after eight years at thomas mcnerney  partners” said dr aguiar “aisling’s latestage investment approach is one that i believe will continue to provide strong investment opportunities i look forward to working with steve drew and the team” dr aguiar currently sits on the board of invitae corporation formerly locus development inc his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson dr aguiar was ceo of genovo inc acquired by targeted genetics a biopharmaceuticals company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals dr aguiar was a vice president and managing director of philadelphia ventures from  to  he is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations dr aguiar received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar dr aguiar was also a luce fellow and is a chartered financial analyst about aisling capital aisling capital is a leading investment firm that invests in products technologies and global businesses that advance health aisling capital is led by a group of investment professionals with diverse backgrounds in industry science and finance the team’s complementary backgrounds give aisling capital unique perspective on the key players events and forces shaping the life science industry and allow the fund to identify investment opportunities in working with our portfolio companies the principals of aisling capital seek to provide the financing relationships and guidance needed to build highly successful companies source aisling capital take your pick buyouts delivers exclusive news and analysis about private equity deals fundraising topquartile managers and more get your free trial or subscribe now vc journal provides exclusive news and analysis about venture capital deals fundraising topquartile investors and more get your free trial or subscribe now sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian bain capital double impact funds two companies by iris dorbian midocean to sell water pik for  bln by luisa beltran carlyle to invest in zerochaos by luisa beltran awake security nabs over  mln from greylock and bain capital ventures by iris dorbian thoma bravo to sell sparta systems to new mountain by iris dorbian the pe hub podcast episode two by staff report post capital sells bhs specialty chemicals by iris dorbian eric aguiar author at law enforcement today home let radio show categories news patrol fallen law  legal technology training video products shop by brand tommie copper vertx shop by category apparel camouflage compression tactical concealed carry bags pants shirts firearm accessories hunting shop by gender mens womens library law enforcement today store home let radio show categories news patrol fallen law  legal technology training video products shop by brand tommie copper vertx shop by category apparel camouflage compression tactical concealed carry bags pants shirts firearm accessories hunting shop by gender mens womens library law enforcement today store author eric aguiar officer eric aguiar llb has a law degree and several years of police experience many of his articles are currently being used for training purposes by various entities he has a passion for officer safety and for improving the communitypolice relationship the disparity that exists between the publics expectation of police services and what the department is actually capable of is of grave concern the amount of police officer injury and death that has been occurring for several years is alarming minimum training requirements must be updated to meet the current needs and dangers featured   posts   training challenges and benefits to social media eric aguiar posted on november   social media is it a good or bad thing social media is a tool which is used for bridging the gap between information and people though the information is often polemic social media itself is not to blame that there … continue reading  k views body cameras   featured   posts   social media judgement cam eric aguiar posted on august   imagine being in a profession where you must make split second decisions that have the potential of causing injury or death to yourself or others rather than being able to devote your total attention to the rapidly evolving incident your … continue reading   views featured   posts peaceably assemble eric aguiar posted on july   special interest groups have been seeking havoc on urban areas claiming to come under the guise of peaceful assembly however interrupting the flow of traffic yelling disrespectful profanity and making death threats to law enforcement and general unruliness isn’t by … continue reading   views featured   leadership   posts the time experience continuum as it applies to leadership eric aguiar posted on june   what if you were sent to the academy and after graduation were kept in an office for thirty years when sitting in front of a panel for the police chief position you could technically say that you have thirty years … continue reading   views featured   posts we the people eric aguiar posted on may   law is supposed to be the reflection of social need the problem today is that it has become the reflection of the voice of special interest groups that represent the minority of the population as compared to “we the people” … continue reading   views featured   patrol   posts promotional structure analysis eric aguiar posted on may   when somebody is given a promotion big or small it must be realized that that individual is being given a piece of the steering wheel of the department that is why it is paramount that the following criteria be included … continue reading   views featured   patrol   posts police the prejudicial task force eric aguiar posted on march   the current state of disrespect that the community displays towards police is repugnant but a recent discovery may bring this into context don’t take the vehement disrespect that the public displays towards you personally after much reflection it has occurred … continue reading   views featured   gone but never forgotten   officer down   posts in remembrance of me eric aguiar posted on december   in previous articles i have quoted several great leaders general sun tzu fan hsiao and phil jackson naming only a few the purpose of that was to show the timelessness of leadership its core principles and the way of true … continue reading  46 views featured   leadership   posts response ability eric aguiar posted on december   there are individuals of a despicable lazy and selfindulgent nature in the world some of them are contaminants in the rank and file of every profession the profession i love law enforcement regretfully is no different the disclaimer that i … continue reading  49 views featured   leadership   posts unless things change eric aguiar posted on november   the flaw is structural in nature and is a byproduct of several things the political appointment of police leadership lack of training of the rank and file a society that despite its ignorance is allowed to orchestrate the public safety … continue reading   views older posts stay updated get the recent popular stories straight into your inbox site map about us advertise writers library contact us submit an article community login register most viewed posts what your dispatcher really thinks about you 6 national telecommunicator’s week  top  things your dispatcher wants you to know 9 president trump confirms promise for law and order 6 mayor i didn’t know we were serving pig tonight 4  copyright law enforcement today  all rights reserved press enterreturn to begin your search eric o aguiar  providence ri  intelius sign in we found eric o aguiar in providence ri eric o aguiar intelius found that eric o aguiar is a male between  and 4 years old from providence ri we have connected them to  addresses  phones and  relatives or associates get report now age eric o aguiar is in his s eric has lived in providence ri boston ma somerset ma erics relatives alexa aguiar nicole aguiar ana dejesus eric o aguiar zodiac signlibra gendermale get report now want to know more about eric get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about eric or use our people search engine to find others get background check on eric o aguiar get a criminal check on eric o aguiar get a public record report on eric o aguiar get a people search report on eric o aguiar eric o aguiars contact information known cities lived in find out where eric o aguiar has lived as well as eric o aguiars phone numbers and email addresses eric o aguiar has lived in  states rhode island address for eric o aguiar 4 a s providence ri has lived in providence ri boston ma get full address report phone numbers associated with eric o aguiar    somerset ma    somerset ma 6   boston ma get full phone report email addresses associated with eric o aguiar get email report eric o aguiars social network and potential email matches find out potential social network profiles and potential email usernamed for eric o aguiar eric o aguiars known social networks and potential email matches find all of eric o aguiars social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches eric aguiar username matches ericaguiar aguiareric ericaguiar aguiareric ericaguiar aguiareric ericaguiar aguiareric eaguiar popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches e aguiar intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here eric aguiar md  aisling capital toggle navigation team aisling capital team aisling capital is led by a group of investment professionals with diverse backgrounds in industry science and finance the team’s complementary backgrounds give aisling capital unique perspective on the key players events and forces shaping the life science industry and allow the fund to identify investment opportunities in working with our portfolio companies the principals of aisling capital seek to provide the financing relationships and guidance needed to build highly successful companies steven a elms managing partner steven a elms mr elms joined aisling in july of  and currently serves as one of the managing partners previously he was a principal in the life sciences investment banking group of hq during his five years at hq mr elms was involved in over  financing and ma transactions helping clients raise in excess of  billion in capital prior to hq mr elms traded mortgagebacked securities at donaldson lufkin  jenrette his previous healthcare sector experience includes over two years as a pharmaceutical sales representative for marion laboratories and two years as a consultant for the wilkerson group mr elms currently serves as a director of adma biologics earlens and loxo oncology previously he served as a director of advion biosciences ambit biosciences archimica cooperatief avera pharmaceuticals bioenvision cenerx biopharma cidara therapeutics lensar nextwave pharmaceuticals novazyme pharmaceuticals pernix therapeutics scerene healthcare and tria beauty and was chairman of the board of adams respiratory therapeutics map pharmaceuticals and oculex pharmaceuticals mr elms received his mba from the kellogg graduate school of management at northwestern university and his ba in human biology from stanford university andrew schiff md managing partner andrew schiff md dr schiff joined aisling in september of 999 and currently serves as one of the managing partners prior to aisling capital dr schiff practiced internal medicine for six years at the new york presbyterian hospital where he maintains his position as a clinical assistant professor of medicine dr schiff currently serves as a director of armgo pharma powervision and zeltiq aesthetics and as a board observer of zavante therapeutics prior board service includes adams respiratory therapeutics agile therapeutics arginox pharmaceuticals barrier therapeutics bioenvision cardiokine cempra pharmaceuticals miramar labs myogen skinmedica sirion therapeutics transenterix and quintiles board observer he is a longtime supporter and board member of the visiting nurse service of new york dr schiff received his md from cornell university medical college his mba from columbia university and his bs with honors in neuroscience from brown university dov a goldstein md managing partner dov a goldstein md dr goldstein joined aisling in 6 and currently serves as one of the managing partners prior to joining aisling dr goldstein served as executive vice president and chief financial officer of vicuron pharmaceuticals for five years up until its acquisition by pfizer while at vicuron pharmaceuticals he raised over  million in an ipo pipe followon and block trade transactions he led the valuation and finance due diligence for the merger with biosearch italia nuovo mercato biomi the first us and italian publictopublic company merger he also ran the investor relations and press relations efforts for the company prior to vicuron dr goldstein was director of venture analysis at healthcare ventures he also completed an internship in the department of medicine at columbiapresbyterian hospital dr goldstein currently serves as a director of adma biologics cempra pharmaceuticals and esperion therapeutics previously he served as a director of durata therapeutics acquired by actavis loxo oncology also served as chief financial officer and topaz pharmaceuticals acquired by sanofi and on other private company boards dr goldstein received his md from yale school of medicine he received his mba from columbia business school and his bs with honors from stanford university dennis j purcell founder and senior advisor dennis j purcell mr purcell is the original founder of aisling capital llc and currently serves as a senior advisor to aisling previously he served as the senior managing partner prior to aisling capital mr purcell served as managing director of the life sciences investment banking group at chase hq formerly hambrecht  quist “hq” for over five years while at hq he was directly involved with over two hundred completed transactions and supervised over  billion of financing and advisory assignments in the pharmaceutical biotechnology and medical products industries during his tenure bioworld and other industry publications cited hq as the leading underwriter of life sciences securities prior to joining hq mr purcell was a managing director in the healthcare group at painewebber inc mr purcell is a frequent commentator on the industry and has been honored in the “biotech hall of fame” by genetic engineering news named to the biotechnology allstars list by forbes asap honored as one of the top  irishamerican businessmen and cited as one of the top  contributors to the biotechnology industry mr purcell has served as a director of aton pharma bridge pharmaceuticals cengent therapeutics dynova laboratories paratek pharmaceuticals valentis and xanodyne pharmaceuticals he has served as a member of the advisory council at harvard medical school the board of directors of the biotechnology industry association as well as the new york biotechnology association the irvington institute and on the board of lek consulting he currently sits on the board of real endpoints summus global inc life science leader magazine –editorial advisory board ny bio association and is a member of the university of delaware investment visiting committee member mr purcell received his mba from harvard university and his bs in accounting from the university of delaware eric aguiar md partner eric aguiar md dr aguiar joined aisling in  prior to joining aisling dr aguiar was a partner at thomas mcnerney and partners a  million health care focused venture capital and growth equity fund from  dr aguiar was a managing director of healthcare ventures a health care venture capital fund from  he currently sits on the boards of biohaven and invitae corporation his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson he was ceo of genovo inc acquired by targeted genetics a biopharmaceutical company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals he was a vice president and managing director of philadelphia ventures from  to  dr aguiar is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations he received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar he was also a luce fellow and is a chartered financial analyst aftab r kherani md partner aftab r kherani md dr kherani joined aisling in  and currently serves as a partner previously dr kherani was an engagement manager for two years at mckinsey  company where he was a member of the pharmaceutical medical product and private equity practices prior to mckinsey dr kherani was a chief resident in surgery at duke university medical center where he completed his residency in general surgery he also completed a twoyear postdoctoral research fellowship investigating treatments for heart failure and arrhythmia at columbia university college of physicians  surgeons while at columbia he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of new york presbyterian hospital dr kherani currently serves as a director of spirox and transenterix and as a board observer at armgo pharma earlens loxo oncology syros pharmaceuticals and t biosystems dr kherani received his md from duke university school of medicine where he was a howard hughes medical institute research fellowship recipient he also received his bs in biology and ab in economics from duke both magna cum laude graduating phi beta kappa stacey d seltzer partner stacey d seltzer ms seltzer joined aisling in  and currently serves as a partner previously ms seltzer was at scheringplough where she held roles in business development marketing and sales most recently serving as the us scheringplough brand lead for zetia while in business development ms seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions ranging from inlicensing deals to broad development and commercialization alliances prior to scheringplough ms seltzer was the director of business development for akceli a biotechnology company developing cellbased microarrays ms seltzer began her career as a management consultant for mckinsey  company ms seltzer serves as a director of aimmune therapeutics miramar labs and promentis pharmaceuticals and as a board observer of prolacta bioscience previously she served as a board observer for agile therapeutics durata therapeutics acquired by actavis and zeltiq aesthetics she also acted as the aisling representative for its investment in precision dermatology acquired by valeant and was closely involved in aisling’s investments in cytos dermira and powervision ms seltzer received her mba from the wharton school at the university of pennsylvania where she was a palmer scholar she received her ms and bs from yale university awarded cum laude in molecular biophysics and biochemistry josh bilenker md operating partner josh bilenker md dr bilenker joined aisling in 6 and currently serves as an operating partner he is president and chief executive officer of loxo oncology an aisling capital iii portfolio company prior to aisling dr bilenker served as a medical officer in the office of oncology drug products at the us food and drug administration for two years while at the fda he conducted clinical reviews of indstage and licensed biologic oncology products prior to joining the fda dr bilenker trained at the university of pennsylvania in internal medicine and medical oncology earning board certification in these specialties dr bilenker currently serves as a director of loxo oncology and viewray previously he served as a director of lensar roka bioscience and t biosystems and as a board observer at aragon pharmaceuticals he is also a board member of the nccn foundation and of bioenterprise dr bilenker received his md from the johns hopkins school of medicine he received his ab from princeton awarded summa cum laude in english scott braunstein md operating partner scott braunstein md dr braunstein serves as an operating partner at aisling capital he is senior vice president strategy and corporate development at pacira pharmaceuticals dr braunstein spent  years as a healthcare analyst and portfolio manager at jp morgan asset management where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates he reviewed pharmaceutical company strategies business models and management teams and provided stock recommendations for the jp morgan asset equity group dr braunstein serves as a director of esperion therapeutics stat medical and the cornell alumni association for the college of agriculture and life sciences dr braunstein received his md from the albert einstein college of medicine and completed his residency in internal medicine at cornell universitynew york hospital he received his bs from cornell university ayman sabi operating partner ayman sabi mr sabi is an independent consultant serving as an operating partner at aisling capital he is the founder of sabi medical group bv and a seasoned entrepreneur with almost  years of fiscal strategic and operational leadership mr sabi founded and led sabi ventures and sabi trading and contracting inc which focused on international trade retail and real estate formerly mr sabi was ceo andor director of white house  black market inc acquired by chico’s inc in  roadhouse grill inc ipo 996 nasdaq new global llc shopping centers sold  and national retail group inc mr sabi has a bs from north carolina state university wonpyo yun analyst wonpyo yun mr yun joined aisling in july  and serves as an analyst previously mr yun was an analyst in the healthcare investment banking group at credit suisse in new york mr yun holds an ab in molecular biology awarded magna cum laude from princeton university where he also received a certificate in finance robert j wenzel chief financial officer robert j wenzel mr wenzel joined aisling in june  and has served as chief financial officer since april  having previously served as controller for nine years for  years prior to joining aisling he was vice president at lazard alternative investments “lazard” where he supervised the financial reporting of several domestic and offshore private equity funds prior to joining lazard mr wenzel began his career at eisner  lubin llp a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele attaining the role of senior accountant mr wenzel received his bba in accounting from baruch college in 99 and holds his certified public accountant license in the state of new york he is also a member of the american institute of certified public accountants and the new york state society of certified public accountants hannah wieder controller hannah wieder ms wieder joined aisling in march  and serves as the controller prior to joining aisling she was an audit manager in the wealth  asset management practice at ernst  young where her focus was on private equity ms wieder also spent six years in the financial services group at cohnreznick a midsize public accounting firm where she attained the role of audit manager and directed the annual audits of various clients within the financial services industry including private equity funds funds of funds and management companies ms wieder received her ms in accountancy from the zicklin school of business at baruch college and received her bs in business management and finance awarded magna cum laude from brooklyn college she is a certified public accountant licensed in the state of new york and is a member of the american institute of certified public accountants and the new york state society of certified public accountants jan hoerrner director of investor relations and marketing jan hoerrner ms hoerrner joined aisling in october of  and serves as the director of investor relations and marketing at aisling capital in this role ms hoerrner manages relationships with over eighty limited partners and is a key contributor in aisling’s fundraising and marketing efforts previously ms hoerrner was with hq a leading underwriter and strategic advisor to the biotechnology industry during her five years at hq ms hoerrner was responsible for coordinating their healthcare conferences and also served as administrative manager for the new york office ms hoerrner received her bs in business administration from bryant university aisling capital welcomes eric aguiar as partner aisling capital welcomes eric aguiar as partner jan   6 et from aisling capital new york jan   prnewswire  aisling capital a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products services and technologies announced that eric aguiar md has joined the firm as a partner dr aguiar who brings to aisling experience in drug development commercialization and strategic leadership will invest in biopharma opportunities across a range of therapeutic areas and stages of development we are delighted to welcome eric to the team said steve elms managing partner at aisling capital many of us have had the pleasure of working with eric over the years witnessing firsthand the business acumen and drug development and commercial expertise that he brings to each endeavor—and were thrilled hell now be applying those strengths as a member of aislings investing practice his proven track record as an operator and entrepreneur coupled with his extensive network across the healthcare industry will also make him a highly valued resource to our portfolio eric has over  years of experience in the healthcare industry in a variety of clinical business strategy product and technology leadership roles we are delighted to welcome him to aisling capital said drew schiff managing partner at aisling capital prior to joining aisling dr aguiar was a partner at thomas mcnerney  partners and before that he was a managing director of healthcare ventures both healthcare focused venture capital firms i am very excited to join aisling capital after eight years at thomas mcnerney  partners said dr aguiar aislings latestage investment approach is one that i believe will continue to provide strong investment opportunities i look forward to working with steve drew and the team dr aguiar currently sits on the board of invitae corporation formerly locus development inc his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson dr aguiar was ceo of genovo inc acquired by targeted genetics a biopharmaceuticals company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals dr aguiar was a vice president and managing director of philadelphia ventures from  to  he is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations dr aguiar received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar dr aguiar was also a luce fellow and is a chartered financial analyst about aisling capital aisling capital is a leading investment firm that invests in products technologies and global businesses that advance health  aisling capital is led by a group of investment professionals with diverse backgrounds in industry science and finance the teams complementary backgrounds give aisling capital unique perspective on the key players events and forces shaping the life science industry and allow the fund to identify investment opportunities in working with our portfolio companies the principals of aisling capital seek to provide the financing relationships and guidance needed to build highly successful companies source aisling capital related links httpwwwaislingcapitalcom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more aug   4 et preview scott braunstein joins aisling capital as operating partner my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search thomas mcnerney  partners home profile team companies news contact professionals james thomas alex zisson eric aguiar md kathleen tune jason brown phd susan haedt kristi lacroix eric aguiar md advisoreric was a partner at thomas mcnerney  partners from  to  prior to joining thomas mcnerney he was a managing director of healthcare ventures a health care focused venture capital firm from  eric is currently a partner at aisling capital eric currently sits on the board of invitae corporation formerly locus development inc his prior board seats have included amarin oriel therapeutics inc acquired by novartis ag virdante pharmaceuticals inc acquired by momenta pharmaceuticals cardiokine inc acquired by cornerstone therapeutics skinmedica inc acquired by allergan vaxinate inc metaphore and d pharmaceuticals acquired by johnson  johnson eric was ceo of genovo inc acquired by targeted genetics a biopharmaceuticals company that specialized in gene delivery and gene regulation he was also executive director of theratech inc acquired by watson pharmaceuticals eric was a vice president and managing director of philadelphia ventures from  to  he is a member of the board of overseers of the tufts school of medicine and a member of the council on foreign relations eric received his medical degree with honors from harvard medical school he graduated with honors from cornell university as a college scholar eric was also a luce fellow and is a chartered financial analyst   thomas mcnerney  partners  all rights reserved